Lancet Onco.l 2023; 24: 744–56. 5 Shitara, K. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020; 382: 2419-30.

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

Research Summary Trastuzumab Deruxtecan in Metastatic Breast Cancer December 4, 2024 DOI: 10.1056/NEJMdo007781 Save ...

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

WILMINGTON, Del., October 01, 2024--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and ...

Researchers think that trastuzumab deruxtecan might help people with stomach cancer or gastro oesophageal junction cancer that has many HER2 receptors. When you agree to join the trial, the trial team ...

AstraZeneca’s latest clinical study, officially titled ‘REal-world Study of Trastuzumab deruXtecan in Patients With unresectabLe or Metastatic Breast Cancer Expressing HER2-lOw From BulgaRia ...

AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase 3b clinical study titled ‘DESTINY-Breast15’ to evaluate the safety and efficacy of Trastuzumab Deruxtecan (T-DXd) in ...

Trastuzumab deruxtecan is a type of drug called an antibody drug conjugate. It is trastuzumab with a chemotherapy like drug attached to it. Deruxtecan is the chemotherapy like drug. Trastuzumab finds ...

Topline results were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki in combination with pertuzumab as a first-line treatment for patients with human epidermal growth ...

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 ...

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...